Alvocidib

Generic Name: Alvocidib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀ClNO_₅

CAS Number: 146426-40-6

Unique Ingredient Identifier: 45AD6X575G

Background: Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

Indication: Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Flavopiridol

First Posted Date: 2007-03-09

Last Posted Date: 2018-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00445341

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: alvocidib
Drug: cytarabine
Drug: mitoxantrone hydrochloride

First Posted Date: 2006-12-05

Last Posted Date: 2015-08-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00407966

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: alvocidib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-09-15

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00377104

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer
Adenocarcinoma of the Pancreas

Interventions: Drug: alvocidib
Drug: docetaxel

First Posted Date: 2006-05-31

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00331682

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: vorinostat
Other: pharmacological study

First Posted Date: 2006-05-11

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00324480

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Phase 1

Completed

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Relapsing Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: alvocidib
Drug: vorinostat

First Posted Date: 2006-01-18

Last Posted Date: 2013-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00278330

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Phase 1

Terminated

Conditions: Adult Lymphocyte Predominant Hodgkin Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: alvocidib

First Posted Date: 2005-06-03

Last Posted Date: 2016-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00112723

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2005-06-03

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00112684

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Phase 1

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: alvocidib

First Posted Date: 2005-01-10

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT00101231

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Gastrointestinal Stromal Tumor
Recurrent Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: alvocidib
Drug: doxorubicin hydrochloride

First Posted Date: 2004-12-08

Last Posted Date: 2013-03-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00098579

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy